Immune checkpoint inhibitors (ICI)-containing therapy for advanced or recurrent non-small cell lung cancer (NSCLC) are not completed by some responders for reasons other than progressive disease (PD).
The proportion of patients who discontinue ICI and the length of their treatment-free status are unclear.
